Quality of life with advanced metastatic prostate cancer.

Resnick MJ, Penson DF
Urol Clin North Am. 2012 39 (4): 505-15

PMID: 23084527 · DOI:10.1016/j.ucl.2012.07.007

The health-related quality-of-life (HRQOL) implications of advanced metastatic prostate cancer are variable. There are several different HRQOL instruments that measure domains germane to patients with advanced metastatic disease. The burden of prostate cancer is inversely related to the magnitude of HRQOL declines. Treatment with androgen deprivation therapy commonly results in HRQOL declines that have served as the impetus for intermittent therapy. Conversely, chemotherapeutic agents have been associated with improvements in functional status for men with castrate-resistant disease. Emerging therapies may result in significant HRQOL improvements in this population, and careful prospective evaluation of patient-reported outcomes will be required.

Copyright © 2012 Elsevier Inc. All rights reserved.

MeSH Terms (18)

Androgen Antagonists Antibodies, Monoclonal, Humanized Antineoplastic Agents Bone Neoplasms Denosumab Diphosphonates Disease Progression Docetaxel Health Status Indicators Humans Imidazoles Male Mitoxantrone Prostatic Neoplasms Quality of Life Taxoids Treatment Outcome Zoledronic Acid

Connections (2)

This publication is referenced by other Labnodes entities: